Abstract
Inflammatory breast cancer has poor prognosis. Without systemic therapy, the 5-year survival was 4 %. Since 1970s, with the introduction of neoadjuvant chemotherapy in the treatment of this tumor, the prognosis has changed. The first attempt of systemic therapy was done with 5-FU given for long time but with improvement in DFS. Later, the incorporation of chemoimmunotherapy based on BCG, however, due to the lack of specificity and the same results without BCG, this modality was abandoned. Finally, regimens based on anthracyclines and taxanes have become the standard of care, not to mention the importance of multimodal treatment.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Wang CC, Griscom NT. Inflammatory carcinoma of the breast. Results following orthovoltage and supervoltage radiation therapy. Clin Radiol. 1964;15:167–74.
Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 2005;22:67–73.
Bozzetti F, Saccozzi R, De Lena M, Salvadori B. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981;18:355–61.
De la Garza J, de la Huerta R, Torres R, Sánchez-Basurto C. Different management of inflammatory carcinoma, ASCO Meeting. Denver; 1977 Abstract C-32.
De la Garza J. Cáncer inflamatorio de la glándula mamaria. Experiencia de 6 años con QT. RT. Cir Ciruj. 1977;45(6):351–7.
Barker JL, Montague E, Peters LJ. Clinical experience with irradiation of inflammatory carcinoma of the breast with or without elective chemotherapy. Cancer. 1980;45:625–9.
Zytherberg B, Salat-Baroux J, Ravina JH, et al. Intial Chemoimmunotheropy in inflammatory cancinoma of the breast cancer 1982:IS:1537-43
Israel L, Breau JL, Morere JF. Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. Cancer. 1986;57:24–8.
Hanna MG, Zbar B, Rapp HJ. Histopathology of tumor regression after intralesional injection of mycobacterium bovis. I. Tumor growth and metastases. J Natl Cancer Inst. 1972;48:1441–55.
Zbar B, Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of Mycobacterium bovis. Science. 1971;772:271–3.
Wiseman C, Jessup JM, Smith TL, et al. Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor CelVBCG immunotherapy. Cancer. 1982;49:1266–71.
Ueno NT, Buzdar AU, Singletary SE, et al. Combined- modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson cancer center. Cancer Chemother Pharmacol. 1997;40:321–9.
Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–8.
Veyret C, Levy CH, Chollet PH, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy. Ten-year results from the French Adjuvant Study Group GETIS 02 trial. Cancer. 2006;107:2535–44.
Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990;65:851–5.
De Boer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol. 2000;11:1147–53.
Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92:1775–82.
Dan Costa S, Sibylle L, Kaufmann M, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2009;28:83–91.
Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200–8.
Cristofanilli M, González-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the MD Anderson cancer center experience. Clin Breast Cancer. 2004;4:415–9.
Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067–74.
Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo Celtic Cooperative Oncology Group study. J Clin Oncol. 2005;23:2988–95.
Yang CH, Cristofanilli M. Systemic treatments for inflammatory breast cancer. Breast Dis. 2005;22:55–65.
Adkins D, Brown R, Trinkaus K, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol. 1999;17:2006–14.
Cagnoni PJ, Nieto Y, Shpall E, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998;16:1661–8.
Somlo G, Frankel P, Chow W, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004;22:1839–48.
Schwartzberg L, Weaver C, Lewkow L, et al. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant. 1999;24:981–7.
Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999;81:449–56.
Arun B, Slack R, Gehan E, et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999;85:93–9.
Bertucci F, Tarpin C, Charafe-Jauffret E, et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 2004;33:913–20.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Arce-Salinas, C., Morales-Vasquez, F., Lara-Medina, F., Villarreal-Colin, S.P. (2013). Chemotherapy in Inflammatory Breast Cancer. In: de la Garza-Salazar, J., Meneses-Garcia, A., Arce-Salinas, C. (eds) Inflammatory Breast Cancer. Springer, London. https://doi.org/10.1007/978-0-85729-991-8_6
Download citation
DOI: https://doi.org/10.1007/978-0-85729-991-8_6
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-990-1
Online ISBN: 978-0-85729-991-8
eBook Packages: MedicineMedicine (R0)